IIT Hyderabad Incubated · ICMR-CCMB Validated

Nano Molecular
Diagnostics in
Microseconds.
Anywhere. Anytime.

Our nano tech healthcare platform delivers femtomolar molecular truth for multiple biomarkers through RNA, DNA and protein-based genome testing — powering Cardio Health, Proactive Beauty, Food & Environment screening from a single pocket-sized device.

1,000× Sensitivity
<30 Seconds
<5 µL Sample
99.1% Accuracy
Multiplex Biomarkers
$52B Total Addressable Market
1,000× More Sensitive than ELISA/qPCR
15 Yrs IIT Hyderabad R&D
TRL 7–8 Ready for Scale Deployment
IIT Hyderabad Incubated
ICMR-CCMB Validated
2 Platform Patents
13 PhD Researchers
99.1% Accuracy
1,000× ELISA/qPCR
Robotic GMP Manufacturing Ready
Pilot-Ready in Months
Zero Capex Reader Model
1-Year Shelf Life at 40°C
IIT Hyderabad Incubated
ICMR-CCMB Validated
2 Platform Patents
13 PhD Researchers
99.1% Accuracy
1,000× ELISA/qPCR
Robotic GMP Manufacturing Ready
Pilot-Ready in Months
Zero Capex Reader Model
1-Year Shelf Life at 40°C
Founders & Partners

Seasoned Founders +
IIT Hyderabad — Our 4th Business Partner

Three world-class founders + one premier Indian institute = the only team built for large-scale hospital deployment, government POC programs, medical-device licensing and beauty-industry white-label partnerships.

AK
Ashish Kumar
Co-Founder · Genomics & AI

Karolinska Institute / Oxford-trained genomics and AI specialist. Bridges cutting-edge molecular science with scalable AI-driven diagnostics architecture. Leads global partnerships and investor relations.

SG
Shiv Govind Singh
Co-Founder · Nano-Biosensors

IIT Hyderabad nano-biosensor pioneer with 7 patents to his name. Architect of the fishing-hook detector platform. Leads all core R&D, IP strategy and TRL 7–8 scale-up roadmap.

AS
Amit Satpathy
Co-Founder · Scale & Partnerships

Vodafone / Reliance scale-up and partnerships veteran. Drives commercial strategy, hospital chain rollouts, government tender programs and beauty-giant white-label deals across India and global markets.

IIT
IIT Hyderabad
4th Institutional Co-Founder

Top new-generation IIT providing 13 PhD researchers embedded in our team, 2 platform patents secured, ICMR-CCMB regulatory validation and 15 years of R&D at 1/10th industry cost. Delivering peer-reviewed IP, government ties and unmatched scientific credibility.

Institutional Co-Founder · Impossible to Replicate
15-Year Technology Roadmap

From Nanomaterials to Handheld Diagnostics
TRL 7–8 Ready for Scale (2010–2024)

Already ICMR-CCMB validated and clinically proven — ready for immediate hospital and government rollout.

2010–12
Nano-Material Synthesis
Foundational research into nano-material properties at IIT Hyderabad labs
2013–14
Bio-Conjugation Protocols
Pioneered molecular conjugation methods enabling selective biomarker capture
2015–16
First Biosensor Prototype
Proof-of-concept nano-biosensor achieving femtomolar sensitivity
2017–18
Multiplex Capability
Simultaneous multi-biomarker detection on single detector platform
2019–20
Patent Filing: Platform IP
2 platform patents filed covering fishing-hook detector and nano-core architecture
2021
COVID RNA Validation
ICMR-CCMB clinical validation: COVID RNA panel achieving 99.1% accuracy
2022
Cardiac Panel Proof
Trop-X, NTProBNP, CRP cardiac biomarker panel validated clinically
2023
X-Home™ Reader Launch
Handheld reader platform completed; robotic GMP manufacturing process ready
2024
TRL 7–8 · Scale Ready
Full platform ready for hospital pilots, government POC, and partner licensing
TRL
7–8
Technology Readiness Level 7–8 — system prototype demonstrated in operational environment, ready for immediate partner deployment in hospitals, governments and diagnostic chains.
The Technology

Our Nano Molecular Platform —
Unlimited Biomarkers, One Reader

X-HOME™ ONE READER UNLIMITED BIOMARKERS Cardiac Trop-X · NTProBNP Skin Beauty 18+ Biomarkers Infectious RNA · DNA Food Safety Pathogen Panel Animal Health Farming Biomarkers Respiratory 8.2B Market Environment Water · Air Protein Panel Genome Testing

The detector remains the same. Changing the "fishing hook" cartridge detects any new biomarker instantly — perfect for hospitals, governments and partners seeking future-proof diagnostics without re-engineering.

🏥
For Hospitals & Govt
Cardiac Biomarkers (Trop-X, NTProBNP, CRP) + Infectious Disease panel
🔬
Medical Device Leaders
Seamless integration into existing POC ecosystems — 1,000× upgrade instantly
Beauty Giants
Skin Protein Profiling for consumer personalization — 18+ biomarkers
🌍
Future Platform
Animal Farming + Food Safety + Environment — same reader, new hooks
X-Home™ Device

Built for Real-World Deployment
& Partnerships

<30s Result Delivery
💧 <5 µL Sample Volume
🎯 99.1% Accuracy vs Industry 92%
🔢 Multiplex Simultaneous Detection
🌡️ 1 Year Shelf Life at 40°C
📡 Anywhere Remote & Rural Ready
💰 Zero CapEx Reader Model Available
🏭 CV <5% Robotic GMP Manufacturing
Market Potential

$52 Billion Opportunity —
Scalable Across Your Sector

Same platform. Zero re-engineering. Four massive verticals addressable with a single swap of the fishing-hook cartridge.

$15.3B Hospitals & Govt POC
Cardiac + Respiratory
9.2% CAGR
$12–30B Beauty Giants
Skincare Molecular
White-label B2B/B2C
$1,000× Medical Device Leaders
License Nano-Core
Instant Upgrade
500M+ Future D2C Self-Care
Households Addressable
Post-B2B Scale
$52B Multi-Vertical Opportunity
Partner Solutions

Tailored Solutions for
Every Audience

🏥
For Large Private Hospitals & Chains
Deploy X-Home™ at Scale

Deploy X-Home™ in emergency, cardiology and pathology departments. Multiplex cardiac panel in <30 seconds. Zero capex reader model available. ICMR-CCMB validated for immediate rollout — pilot-ready for 6,000+ sites.

Request Hospital Demo →
🏛️
For Government Authorities
National POC Programs at Scale

National POC programs for cardiac screening, infectious disease surveillance and rural health. Regulatory runway ready. 1-year 40°C shelf life for remote deployment. Low-cost, high-accuracy biomarker detection at population scale.

Discuss Government POC →
🔬
For Medical Diagnostic Device Leaders
License Our Nano-Biosensor Platform

License our nano-biosensor platform or integrate into your existing readers. 1,000× sensitivity upgrade instantly. Unlimited biomarker future-proofing. Turnkey partnership model — sign licensing MOU + joint validation today.

Explore Licensing MOU →
For Beauty & Skincare Giants
White-Label Molecular Personalization

White-label molecular skin biomarker testing for your consumer apps and retail lines. 18+ biomarkers. Predictive 2–5 year efficacy insights. Instant molecular proof for your claims — B2B licensing or B2C self-care device.

Start Beauty Partnership →
Competitive Edge

Why Only BioKubit Wins —
Molecular Depth at Scale

While others offer surface imaging or bulky clinic machines, BioKubit delivers molecular truth in a pocket-sized platform.

vs Leading Cosmetic / Skin Imaging Devices
Platform Molecular Depth Sensitivity Handheld POC Predictive Insights Biomarker Count
BioKubit X-Home™ RNA/DNA/Protein Femtomolar <30 sec 2–5 Year 18+ Skin
Surface Imaging Devices Surface Only Low ~ Bulky No Visual Only
Lab-Based Genomics Molecular ~ Moderate Clinic Only ~ Limited ~ Few Panels
Consumer Skin Apps Camera Only None Mobile No 0
vs Leading Point-of-Care Health Diagnostic Devices
Platform Sensitivity Multiplex Sample Volume Shelf Life (40°C) Biomarker Flexibility
BioKubit X-Home™ 1,000× ELISA Full Panel <5 µL 1 Year Unlimited
Abbott-style POCT ~ Standard ~ Limited ~ Moderate ~ 6 Months Fixed Panels
ELISA / Lab Benchtop ~ Baseline ~ Some High Volume Cold Chain Slow Iteration
Lateral Flow / Rapid Low Single Only Small Good One Biomarker

"While others offer surface imaging or bulky clinic machines, BioKubit delivers molecular truth in a pocket-sized platform. The only solution ready for hospital chains, government programs, diagnostic leaders and beauty giants alike."

Our Unmatched Moat

4+ Years of Research Excellence +
IIT Hyderabad Partnership = An Unmatched Moat

Impossible for fast-followers to replicate. ~$1M total cost. 15 years of R&D compressed into a deployable platform with regulatory validation and institutional backing.

🛡️
2 Platform Patents
Core fishing-hook detector and nano-biosensor architecture protected by IIT Hyderabad-backed IP — platform-level, not product-level patents
🎓
IIT Hyderabad as 4th Co-Founder
13 PhD researchers permanently embedded. Government access, peer-reviewed publications, and institutional credibility no startup can buy
ICMR-CCMB Validation
India's apex medical research body clinical validation complete — the fastest regulatory fast-track any diagnostic partner could ask for
⏱️
15-Year R&D Head Start
~$1M total cost vs $10M+ for competitors to build equivalent. A decade and a half of nano-material science compressed into deployable form
🔬
Femtomolar Sensitivity
1,000× more sensitive than ELISA/qPCR — detecting biomarkers at concentrations existing platforms physically cannot reach
🔄
Platform Architecture Lock-In
One reader, unlimited biomarkers via cartridge swap. Once partners integrate, switching costs are prohibitive — creating lasting B2B lock-in
Investment Opportunity

$5M Seed Round —
Clear Path to $1B+ Exit

$5M
Seed Round · Open Now

Funds hospital/government pilots + beauty white-label deals. Partners commit $5–25M upfront licensing + royalties + co-branded consumer self-care upside. Clear path to $1B+ exit through beauty-tech acquisitions paid 9–14× revenue.

  • Deploy first 6,000+ sites hospital/govt POC pilot
  • Sign licensing MOU with diagnostic chains and beauty giants
  • Robotic GMP manufacturing scale-up initiated
  • $5–25M upfront licensing + royalties from B2B partners
  • Consumer self-care device planned post-B2B — 500M+ households
  • $1B+ exit via beauty-tech acquisitions at 9–14× revenue multiple
01
Hospital & Govt Pilots
Deploy first 6,000+ sites across hospital chains and government POC programs — building recurring reagent revenue
02
Device Leader Licensing
Sign MOU + joint validation with Abbott-style diagnostic companies — $5–25M upfront + royalties
03
Beauty Giant White-Label
Co-branded consumer self-care deals with L'Oréal-style companies — molecular personalization at retail scale
04
Direct-to-Consumer Scale
500M+ household addressable market through consumer device + recurring cartridge subscriptions
05
$1B+ Exit
Beauty-tech acquisitions paying 9–14× revenue — BioKubit positioned as the molecular diagnostics platform for next-gen personal care
Ready to Partner or Invest

Deploy, License or Invest in
Nano Molecular Diagnostics

Reach out directly to our co-founders for hospital deployments, government POC discussions, licensing MOUs, beauty white-label partnerships or investor conversations.

AK
Ashish Kumar
Co-Founder · Genomics & AI
AS
Amit Satpathy
Co-Founder · Scale & Partnerships
Pilot-Ready in Months

IIT Hyderabad Incubated · ICMR-CCMB Validated · Robotic GMP Manufacturing Ready · Deploy for Hospitals, Diagnostic Chains & Personal Care Brands